Optimization of inhibitors of the tyrosine kinase EphB4. 2. Cellular potency improvement and binding mode validation by X-ray crystallography

Journal of Medicinal Chemistry

Volumn 56, Issue 1, 2013, Pages 84-96

  Lafleur, Karine ^a   Dong, Jing ^a   Huang, Danzhi ^a   Caflisch, Amedeo ^a   Nevado, Cristina ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR B4 INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG INHIBITION; DRUG POTENCY; ENZYME ASSAY; FEMALE; MOLECULAR DYNAMICS; NONHUMAN; VALIDATION PROCESS; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; COMPUTER SIMULATION; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, EPHA3; RECEPTOR, EPHB4; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84872309000     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301187e     Document Type: Article

References (34)

1. Pasquale, E. B. Eph receptor signalling casts a wide net on cell behaviour Nat. Rev. Mol. Cell. Biol. 2005, 6, 462-475
2. Adams, R. H. Vascular patterning by Eph receptor tyrosine kinases and ephrins Semin. Cell. Dev. Biol. 2002, 13, 55-60
3. Martiny-Baron, G.; Holzer, P.; Billy, E.; Schnell, C.; Brueggen, J.; Ferretti, M.; Schmiedeberg, N.; Wood, J. M.; Furet, P.; Imbach, P. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis Angiogenesis 2010, 13, 259-267
4. Bardelle, C.; Cross, D.; Davenport, S.; Kettle, J. G.; Ko, E. J.; Leach, A. G.; Mortlock, A.; Read, J.; Roberts, N. J.; Robins, P.; Williams, E. J. Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines Bioorg. Med. Chem. Lett. 2008, 18, 2776-2780
5. Miyazaki, Y.; Nakano, M.; Sato, H.; Truesdale, A. T.; Stuart, J. D.; Nartey, E. N.; Hightower, K. E.; Kane-Carson, L. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases Bioorg. Med. Chem. Lett. 2007, 17, 250-254
6. Lafleur, K.; Huang, D.; Zhou, T.; Caflisch, A.; Nevado, C. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4) J. Med. Chem. 2009, 52, 6433-6446
7. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "gatekeeper door": exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681-2694
8. Mitchell, S. A.; Danca, M. D.; Blomgren, P. A.; Darrow, J. W.; Currie, K. S.; Kropf, J. E.; Lee, S. H.; Gallion, S. L.; Xiong, J. M.; Pippin, D. A.; DeSimone, R. W.; Brittelli, D. R.; Eustice, D. C.; Bourret, A.; Hill-Drzewi, M.; Maciejewski, P. M.; Elkin, L. L. Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4 Bioorg. Med. Chem. Lett. 2009, 19, 6991-6995
9. Noberini, R.; Lamberto, I.; Pasquale, E. B. Targeting Eph receptors with peptides and small molecules: progress and challenges Semin. Cell. Dev. Biol. 2012, 23, 51-57
10. Kolb, P.; Kipouros, C. B.; Huang, D.; Caflisch, A. Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors Proteins 2008, 73, 11-18
11. Bamborough, P.; Angell, R. M.; Bhamra, I.; Brown, D.; Bull, J.; Christopher, J. A.; Cooper, A. W.; Fazal, L. H.; Giordano, I.; Hind, L.; Patel, V. K.; Ranshaw, L. E.; Sims, M. J.; Skone, P. A.; Smith, K. J.; Vickerstaff, E.; Washington, M. N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics Bioorg. Med. Chem. Lett. 2007, 17, 4363-4368
12. Jeong, E. J.; Liu, X.; Jia, X.; Chen, J.; Hu, M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions Curr. Drug Metab. 2005, 6, 455-468
13. Manley, P. W.; Drueckes, P.; Fendrich, G.; Furet, P.; Liebetanz, J.; Martiny-Baron, G.; Mestan, J.; Trappe, J.; Wartmann, M.; Fabbro, D. Extended kinase profile and properties of the protein kinase inhibitor nilotinib Biochim. Biophys. 2010, 1804, 445-453
14. Auffinger, P.; Hays, F. A.; Westhof, E.; Ho, P. S. Halogen bonds in biological molecules Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 16789-16794
15. Huber, K.; Brault, L.; Fedorov, O.; Gasser, C.; Filippakopoulos, P.; Bullock, A. N.; Fabbro, D.; Trappe, J.; Schwaller, J.; Knapp, S.; Bracher, F. 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes J. Med. Chem. 2012, 55, 403-413
16. Ishikawa, M.; Hashimoto, Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry J. Med. Chem. 2011, 54, 1539-1554
17. Maier, J. A.; Brugel, T. A.; Sabat, M.; Golebiowski, A.; Laufersweiler, M. J.; VanRens, J. C.; Hopkins, C. R.; De, B.; Hsieh, L. C.; Brown, K. K.; Easwaran, V.; Janusz, M. J. Development of N-4,6-pyrimidine-N-alkyl-N′- phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase Bioorg. Med. Chem. Lett. 2006, 16, 3646-3650
18. Sabat, M.; VanRens, J. C.; Laufersweiler, M. J.; Brugel, T. A.; Maier, J.; Golebiowski, A.; De, B.; Easwaran, V.; Hsieh, L. C.; Walter, R. L.; Mekel, M. J.; Evdokimov, A.; Janusz, M. J. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck) Bioorg. Med. Chem. Lett. 2006, 16, 5973-5977
19. Zagorska, A.; Jurczyk, S.; Pawlowski, M.; Dybala, M.; Nowak, G.; Tatarczynska, E.; Nikiforuk, A.; Chojnacka-Wojcik, E. Synthesis and preliminary pharmacological evaluation of imidazo[2,1-f]purine-2,4-dione derivatives Eur. J. Med. Chem. 2009, 44, 4288-4296
20. Baraldi, P. G.; Preti, D.; Tabrizi, M. A.; Fruttarolo, F.; Romagnoli, R.; Zaid, N. A.; Moorman, A. R.; Merighi, S.; Varani, K.; Borea, P. A. New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists J. Med. Chem. 2005, 48, 4697-4701
21. Baraldi, P. G.; Preti, D.; Tabrizi, M. A.; Romagnoli, R.; Saponaro, G.; Baraldi, S.; Botta, M.; Bernardini, C.; Tafi, A.; Tuccinardi, T.; Martinelli, A.; Varani, K.; Borea, P. A. Structure-activity relationship studies of a new series of imidazo[2,1-f]purinones as potent and selective A(3) adenosine receptor antagonists Bioorg. Med. Chem. 2008, 16, 10281-10294
22. Messaoudi, S.; Treguier, B.; Hamze, A.; Provot, O.; Peyrat, J. F.; De Losada, J. R.; Liu, J. M.; Bignon, J.; Wdzieczak-Bakala, J.; Thoret, S.; Dubois, J.; Brion, J. D.; Alami, M. Isocombretastatins A versus combretastatins A: The forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent J. Med. Chem. 2009, 52, 4538-4542
23. Alcalde, E.; Mesquida, N.; Frigola, J.; Lopez-Perez, S.; Merce, R. Indene-based scaffolds. Design and synthesis of novel serotonin 5-HT6 receptor ligands Org. Biomol. Chem. 2008, 6, 3795-3810
24. Takami, A.; Iwakubo, M.; Okada, Y.; Kawata, T.; Odai, H.; Takahashi, N.; Shindo, K.; Kimura, K.; Tagami, Y.; Miyake, M.; Fukushima, K.; Inagaki, M.; Amano, M.; Kaibuchi, K.; Iijima, H. Design and synthesis of Rho kinase inhibitors (I) Bioorg. Med. Chem. 2004, 12, 2115-2137
25. Bakke, B. A.; McIntosh, M. C.; Turnbull, K. D. Improved alkylation and product stability in phosphotriester formation through quinone methide reactions with dialkyl phosphates J. Org. Chem. 2005, 70, 4338-4345
26. Kumar, S. R.; Singh, J.; Xia, G.; Krasnoperov, V.; Hassanieh, L.; Ley, E. J.; Scehnet, J.; Kumar, N. G.; Hawes, D.; Press, M. F.; Weaver, F. A.; Gill, P. S. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer Am. J. Pathol. 2006, 169, 279-293
27. Stephenson, S. A.; Slomka, S.; Douglas, E. L.; Hewett, P. J.; Hardingham, J. E. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer BMC Mol. Biol. 2001, 2, 15
28. Castellano, G.; Reid, J. F.; Alberti, P.; Carcangiu, M. L.; Tomassetti, A.; Canevari, S. New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies Cancer Res. 2006, 66, 10709-10719
29. Choi, Y.; Syeda, F.; Walker, J. R.; Finerty, P. J., Jr.; Cuerrier, D.; Wojciechowski, A.; Liu, Q.; Dhe-Paganon, S.; Gray, N. S. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 4467-4470
30. Huang, D.; Zhou, T.; Lafleur, K.; Nevado, C.; Caflisch, A. Kinases selectivity potential for inhibitors targeting the ATP binding site: a network analysis Bioinformatics 2010, 26, 198-204
31. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants J. Appl. Crystallogr. 1993, 26, 795-800
32. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1994, 50, 760-763.
33. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40, 658-674
34. Adams, P. D.; Grosse-Kunstleve, R. W.; Hung, L. W.; Ioerger, T. R.; McCoy, A. J.; Moriarty, N. W.; Read, R. J.; Sacchettini, J. C.; Sauter, N. K.; Terwilliger, T. C. PHENIX: building new software for automated crystallographic structure determination Acta Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58, 1948-1954